Sort   by:  
 Page size 
UnknownEffects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
Not available
S-EPMC7615591 | biostudies-literature
UnknownFrailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial.
Not available
S-EPMC11390031 | biostudies-literature
UnknownStudy of Rivaroxaban for Cerebral Venous Thrombosis: A Randomized Controlled Feasibility Trial Comparing Anticoagulation With Rivaroxaban to Standard-of-Care in Symptomatic Cerebral Venous Thrombosis.
Not available
S-EPMC10615774 | biostudies-literature
UnknownImpact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.
Not available
S-EPMC7618536 | biostudies-literature
UnknownEffects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial.
Not available
S-EPMC12274867 | biostudies-literature
UnknownSecond asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy.
Not available
S-EPMC8473558 | biostudies-literature
UnknownAssessment of Discrepancies Between Follow-up Infarct Volume and 90-Day Outcomes Among Patients With Ischemic Stroke Who Received Endovascular Therapy.
Not available
S-EPMC8571657 | biostudies-literature
UnknownMediation of Age and Thrombectomy Outcome by Neuroimaging Markers of Frailty in Patients With Stroke.
Not available
S-EPMC10762575 | biostudies-literature
UnknownImplementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study.
Not available
S-EPMC8940185 | biostudies-literature
UnknownThe P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection.
Not available
S-EPMC10009825 | biostudies-literature
Sort   by:  
 Page size